Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years at the time of consent~2. Relapsed or refractory B-ALL, defined as:~   * First or greater bone marrow relapse from CR, or~  * Any bone marrow relapse after allogeneic hematopoietic stem cell transplant (HSCT); subjects must be at least 100 days from HSCT at the time of screening and off immunosuppressant medication for at least 1 month at the time of screening, and have no active graft-vs-host disease (GVHD), or~  * Refractory B-ALL, defined by not having achieved a CR or CRi after two attempts at remission induction using standard regimens, or~  * Ph+ B-ALL if subjects are intolerant to or ineligible for tyrosine kinase inhibitor (TKI) therapy, or have progressed after at least one line of TKI therapy~3. Morphological evidence of disease in bone marrow (at least 5% blasts)~4. Evidence of CD19 expression~5. Eastern Cooperative Oncology Group (ECOG) performance status between 0 and 2 at the time of screening~6. Adequate pulmonary, renal, hepatic, and cardiac function~7. Adequate central or peripheral vascular access for leukapheresis procedure~Exclusion Criteria:~1. Isolated extramedullary disease relapse~2. Concomitant genetic syndrome or other known bone marrow failure syndrome~3. Burkitt's lymphoma/leukemia or chronic myelogenous leukemia lymphoid blast crisis (p210 BCR-ABL+)~4. Prior malignancy, unless treated with curative intent and with no evidence of active disease present for \> 5 years before screening~5. Prior treatment with any gene therapy product~6. Active hepatitis B, active hepatitis C, or any human immunodeficiency virus (HIV) infection at the time of screening~7. Systemic fungal, bacterial, viral, or other infection that is not controlled, at the time of screening~8. Presence of Grade II-IV (Glucksberg) or B-D (IBMTR) acute or extensive chronic GVHD at the time of screening~9. Active central nervous system (CNS) involvement by malignancy (defined as CNS-3 per National Comprehensive Cancer Network \[NCCN\] guidelines)~10. History of any one of the following cardiovascular conditions within the past 6 months: Class III or IV heart failure as defined by the New York Heart Association (NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease~11. History or presence of clinically relevant CNS pathology such as epilepsy, generalized seizure disorder, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis~12. Participation in an investigational research study using an investigational agent within 30 days of screening~13. History of treatment with a murine-derived biological product other than blinatumomab unless subject has been shown to be negative for human-anti-mouse-antibodies (HAMA) prior to or during screening~14. Pregnant or nursing women~15. Use of prohibited medications:~    1. Steroids: Therapeutic doses of corticosteroids are prohibited within 7 days prior to leukapheresis.~   2. Allogeneic cellular therapy: Donor lymphocyte infusions (DLI) are prohibited within 4 weeks prior to leukapheresis~   3. GVHD therapies: Any drug used for GVHD within 4 weeks prior to leukapheresis~   4. Chemotherapies: Salvage chemotherapy must be stopped at least 1 week prior to leukapheresis~16. Treatment with alemtuzumab within 6 months prior to leukapheresis, or treatment with clofarabine or cladribine within 3 months prior to leukapheresis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- JCAR015 (CD19-targeted CAR T cells) (Type: EXPERIMENTAL): JCAR015 was administered as two intravenous (IV) infusions separated by 14 to 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).